{"filings":[{"id":78284,"accession_number":"0001193125-26-222923","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-05-14T12:45:19+00:00","items":["1.01","1.02","2.01","5.01","3.01","3.03","5.03","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Biogen completes $5.3B acquisition of Apellis; stockholders get $41 cash + CVR up to $4","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer accepted 105.7M shares (~82.4%); merger effective May 14, 2026.","Consideration per share: $41 cash plus CVR worth up to $4 based on SYFOVRE sales milestones.","CVR milestones: $2 if SYFOVRE net sales ≥$1.5B by 2030; $2 if ≥$2B by 2031 (or $4 if second met first).","Apellis common stock delisted from Nasdaq; intends to terminate SEC reporting obligations.","Board resigned; Michael Dambach (Biogen designee) becomes sole director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93160,"accession_number":"0001193125-26-202504","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis amends executive severance plan to accelerate vesting upon change of control in Biogen merger","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation committee approved amendment to Executive Separation Benefits Plan on April 28, 2026, in connection with Biogen merger.","Unvested converted options and RSU awards will accelerate upon termination without cause or for good reason after closing.","'Good Reason' definition modified for C-Level Officers to include changes in scope due to becoming a subsidiary.","Amendment effective upon closing of the merger; applies to each named executive officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104556,"accession_number":"0001193125-26-134916","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Biogen to acquire Apellis for $41/share plus CVRs up to $4, total up to $45/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Biogen to pay $41.00 per share cash upfront plus one CVR per share for Apellis (APLS).","CVRs entitle holders to up to $4.00/share based on SYFOVRE net sales milestones ($1.5B or $2B).","Tender offer to commence for all shares; no stockholder vote required; minimum condition >50% tendered.","Support stockholders owning ~14% of shares agree to tender; termination fee $205M under certain conditions.","Apellis board unanimously recommends; deal expected to close by Sept 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104555,"accession_number":"0001193125-26-084156","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis adds Dr. Mikael Dolsten as independent Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mikael Dolsten elected to Apellis Board as Class I director effective March 1, 2026, serving until the 2027 annual meeting.","Dolsten deemed independent under Nasdaq rules; no committee appointments at this time.","Received initial equity grant: option with $300,000 Black-Scholes value (3-year vest) and RSUs worth $300,000 (1-year cliff vest).","Standard indemnification agreement in place; no family relationships or transactions with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104554,"accession_number":"0001193125-26-010540","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apellis reports preliminary 2025 U.S. net product revenues of $689M; cash $466M; SYFOVRE injections up 17%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2025 preliminary U.S. net product revenues: SYFOVRE $587M, EMPAVELI $102M, total $689M.","SYFOVRE total injection demand grew 17% YoY; ~60% market share in geographic atrophy; prefilled syringe submission planned 1H 2026.","EMPAVELI C3G/IC-MPGN launch: 267 patient start forms in 2025, >5% market penetration; 95% payer coverage.","Cash and cash equivalents ~$466M at Dec 31, 2025; company expects to fund operations to profitability.","Pivotal trials initiated for EMPAVELI in FSGS and DGF; IND for APL-9099 (FcRn) planned 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137438,"accession_number":"0001193125-25-153429","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Apellis enters $275M royalty buy-down with Sobi; reduces Aspaveli royalties 90%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sobi pays Apellis $275M upfront; up to $25M more on EMA approval of Aspaveli for C3G and IC-MPGN.","Royalty obligations under Collaboration Agreement reduced by 90% from closing, subject to cap of 1.45x payments made.","Sixth Street lenders consent to deal; Apellis extends prepayment premium periods on credit facility by one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154756,"accession_number":"0001193125-25-134886","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apellis shareholders elect three Class II directors and ratify Deloitte as auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected A. Sinclair Dunlop (54.1M for, 26.0M withheld), Alec Machiels (62.3M for, 17.8M withheld), Keli Walbert (76.95M for, 3.18M withheld) as Class II directors for three-year terms.","Ratified Deloitte & Touche as independent auditor for FY2025 with 103.9M for, 54.6K against, 116.2K abstain.","Approved non-binding advisory vote on named executive officer compensation: 75.9M for, 4.17M against, 59.9K abstain.","Recommended future say-on-pay votes every year (79.86M for 1-year); company will hold annual advisory votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154755,"accession_number":"0001193125-25-086304","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis appoints Craig A. Wheeler to Board, effective April 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig A. Wheeler elected as Class III director; will serve until 2026 annual meeting.","Appointed to Audit Committee effective May 1, 2025; determined independent under Nasdaq rules.","Received option for 28,195 shares at $18.20 (3-year vest) and 16,483 RSUs (1-year vest).","Wheeler is former CEO of Momenta Pharmaceuticals (acquired by J&J) and current CEO of Headwaters Biotech Advisors.","No arrangements or family relationships with existing directors or executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173264,"accession_number":"0001193125-25-005052","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Apellis reports $709M preliminary FY2024 U.S. net product revenue, COO Townsend to depart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary FY2024 U.S. net product revenues $709M; SYFOVRE $611M (120% YoY growth), EMPAVELI $98M.","Cash and equivalents $410M as of Dec 31, 2024, up from $351M a year earlier.","sNDA for C3G/IC-MPGN expected early 2025; 2H 2025 launch if approved. Phase 3 FSGS and DGF studies planned 2H 2025.","COO Adam Townsend to depart Feb 21, 2025; David Acheson named EVP of commercial.","Keli Walbert elected to Board; ex-U.S. workforce reduced by ~40 employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206780,"accession_number":"0001193125-24-196465","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apellis/Sobi Phase 3 VALIANT meets primary endpoint; 68% proteinuria reduction in C3G/IC-MPGN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Statistically significant 68% proteinuria reduction vs placebo (p<0.0001) at Week 26.","Key secondary endpoints met: composite renal endpoint and ≥50% proteinuria reduction.","Favorable safety profile; no meningitis or serious infections from encapsulated bacteria.","All VALIANT completers enrolled in long-term extension study VALE.","Apellis to file sNDA with FDA in early 2025; Sobi to submit EMA application in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224030,"accession_number":"0001193125-24-155179","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apellis stockholders elect directors, ratify auditor, approve executive pay at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paul Fonteyne elected with 98,837,712 votes for and 5,320,270 withheld; Stephanie Monaghan O'Brien elected with 80,481,023 for and 23,672,152 withheld.","Ratification of Deloitte & Touche as auditor passed with 109,564,727 for, 56,762 against, and 42,951 abstain.","Advisory vote on executive compensation approved with 93,573,357 for, 10,540,010 against, and 44,708 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224029,"accession_number":"0001193125-24-137743","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Apellis closes $375M senior secured term loan; buys out SFJ Pharmaceuticals liability","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Apellis entered $475M credit facility with Sixth Street; initial draw $375M; maturity May 2030 at SOFR+5.75% (1% floor).","Proceeds used to buy out remaining SFJ Pharmaceuticals liability for ~$326M, eliminating $366M in future payments.","Optional $100M draw available if SYFOVRE trailing 3-month sales ≥ $180M and $50M cash minimum met.","Credit facility secured by substantially all assets including IP; liquidity covenant if market cap < $3B.","No scheduled amortization; principal due at maturity; prepayment permitted with premium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243393,"accession_number":"0001193125-24-047073","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Apellis FY2023 revenue $396.6M, SYFOVRE drives 160k+ doses; net loss $528.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 total revenue $396.6M (vs $75.4M in 2022); SYFOVRE $275.2M, EMPAVELI $91.0M.","SYFOVRE: over 160,000 commercial and sample doses distributed in 2023; Q4 net revenue $114.3M.","Net loss $528.6M for 2023 (vs $652.2M in 2022); cash $351.2M as of Dec 31, 2023.","Entered agreements to unwind ~80% of capped calls on convertible notes due 2026; expects ~$100M proceeds.","G&A expenses rose to $500.8M in 2023 (vs $277.2M in 2022) on SYFOVRE commercial launch costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":396591000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243392,"accession_number":"0001193125-24-011699","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis appoints Adam Townsend as Chief Operating Officer, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam Townsend, 47, previously Chief Commercial Officer since Nov 2018, assumes additional COO role.","Townsend's background includes senior leadership roles at Biogen, including SVP of Corporate Development.","No family relationships with directors or executive officers, and no reportable transactions.","Appointment effective January 16, 2024, by the Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243391,"accession_number":"0001193125-24-003998","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apellis reports preliminary Q4 2023 U.S. net product revenue of $138M, full year $366M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 U.S. net product revenue ~$138M: SYFOVRE $114M, EMPAVELI $24M.","Full year 2023 U.S. net product revenue ~$366M: SYFOVRE $275M, EMPAVELI $91M.","SYFOVRE: ~62,000 doses in Q4, ~160,000 total in 2023; ~95% of GA patients use SYFOVRE.","EMPAVELI: 97% compliance; >50% existing and >90% new patients use Injector since Oct approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":396591000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260782,"accession_number":"0001193125-23-294892","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apellis receives negative trend vote on EU MAA for pegcetacoplan; expects CHMP negative opinion in Jan 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP negative trend vote on MAA for intravitreal pegcetacoplan for geographic atrophy (GA) after Dec 13 oral explanation.","Apellis expects CHMP to adopt negative opinion at Jan 22-25, 2024 meeting.","Company plans to appeal and seek re-examination of the opinion.","Pegcetacoplan is for GA secondary to age-related macular degeneration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260781,"accession_number":"0001193125-23-286826","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Apellis updates SYFOVRE label to include rare retinal vasculitis risk; rate 0.01% per injection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated USPI Warnings/Precautions and Postmarketing Experience sections to include retinal vasculitis with/without occlusion.","Estimated rate of retinal vasculitis remains rare at 0.01% per injection, based on over 120,000 injections administered as of Nov 18, 2023.","Label update pursued in collaboration with the FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260780,"accession_number":"0001193125-23-267745","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Apellis enters $300M ATM offering with Cowen; prior Jefferies facility terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Cowen to sell up to $300M of common stock via at-the-market offerings.","Prior $300M ATM with Jefferies terminated; no shares had been sold under that agreement.","Cowen will receive up to 3.0% commission on gross proceeds from sales.","ATM offering made under existing shelf registration statement (File No. 333-269899)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}